ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Induction therapy"

  • 2020 American Transplant Congress

    Causal Relationship between Anti-Thymocyte Globulin Induction Therapy and Development of Monomorphic PTLD in Renal Transplant Recipients

    K. Soliman1, H. Ali2, T. Fulop1, A. Osman3, A. Halawa4

    1Medicine, Medical University of South Carolina, Charleston, SC, 2Medicine, Royal Stoke, Royal Stoke, United Kingdom, 3Medicine, Cairo University, Cairo, Egypt, 4Medicine, University of Liverpool, Liverpool, United Kingdom

    *Purpose: The aim of our study is to explore the causality between ATG and different types of post-transplant lymphoproliferative disorder (PTLD) in renal transplant recipients…
  • 2020 American Transplant Congress

    Maintenance Steroids in the Setting of Alemtuzumab Induction Post-Kidney Transplant Increases Risk of Infection and Hospital Readmission

    A. R. Webb, A. A. Al-Bahou, A. J. Brueckner, A. T. Logan, R. S. Baliga, L. J. Bowman Anger

    Tampa General Hospital, Tampa, FL

    *Purpose: This study sought to assess the safety of steroid-containing maintenance immunosuppression in the setting of alemtuzumab (ALEM) induction.*Methods: Adult (>18 years) kidney transplant recipients…
  • 2020 American Transplant Congress

    Thymoglobulin Induction in Kidney Transplant Recipients: A Single Center Experience Comparing 3 Mg/kg vs 5 Mg/kg Cumulative Dosing

    K. Progar1, S. January1, N. Nesselhauf1, J. Hagopian1, A. Malone2

    1Transplant, Barnes-Jewish Hospital, St. Louis, MO, 2Transplant Nephrology, Washington University, St. Louis, MO

    *Purpose: Beginning in 2016, our center implemented a protocol change to thymoglobulin (r-ATG) induction dosing in kidney transplant recipients at low rejection risk from 5…
  • 2020 American Transplant Congress

    Single Center Experience Using Low-Dose Antithymocycte Globulin for Induction Following Heart Transplant

    T. J. ONeill IV, G. Jao, A. Kelkar, B. Pisani

    Wake Forest Baptist Health System, Winston Salem, NC

    *Purpose: The use of induction therapy after cardiac transplantation remains highly variable, not only in terms of which agent is used, but whether it is…
  • 2020 American Transplant Congress

    Navigating Through IgM Antibodies in Deceased Donor Kidney Transplants from A2/A2B Donors to B Recipients

    M. Kueht, A. Gamilla-Crudo, S. Hussain, R. Kulkarni, J. Fair, H. Stevenson-Lerner, M. Mujtaba

    University of Texas Medical Branch, Galveston, TX

    *Purpose: Multiple studies have shown acceptable deceased donor transplant (DDT) outcomes from A2 and A2B donors into B recipients; however, concerns remain for acute rejection…
  • 2020 American Transplant Congress

    Short Term Outcomes in Kidney Transplant Patients Receiving De Novo Belatacept with Anti-Thymocyte Globulin Induction

    B. Carlson, P. Cabrera, T. Harrison, K. Tejani, A. Centeno

    Pharmacy, Jackson Memorial Hospital, Miami, FL

    *Purpose: Mainstay immunosuppressive therapy after kidney transplant is a calcineurin inhibitor (CNI) based regimen. Nephrotoxicity is a common adverse effect of CNIs which can lead…
  • 2020 American Transplant Congress

    Peri-Operative Extracorporeal Photopheresis in High Risk Patients after Heart Transplantation

    A. Zuckermann1, J. Gökler1, N. Worel2, P. Angleitner1, E. Ceran1, E. Ceran1, N. Neuber1, P. Kaiser1, G. Laufer1, A. Aliabadi-Zuckermann1

    1Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Department of Transfusion Medicine, Medical University of Vienna, Vienna, Austria

    *Purpose: Extracorporeal photopheresis (ECP) is an established therapy for treatment of heart transplant rejection and is also applied for rejection prevention in the perioperative setting…
  • 2020 American Transplant Congress

    Anti-HLA IgM Antibodies are Unaffected by Imlifidase (IdeS) Treatment

    A. Runström1, R. Bockermann1, K. Sjöholm1, K. M. Roupé1, Å. Schiött1, L. Winstedt1, C. Kjellman1, T. Lorant2

    1Hansa Biopharma AB, Lund, Sweden, 2Section of Transplantation Surgery, Department of Surgical Sciences, Uppsala, Sweden

    *Purpose: The immunoglobulin G (IgG)-degrading cysteine protease, imlifidase (IdeS) is an IgG endopeptidase under development as a rapid desensitization treatment in kidney transplantation. Imlifidase is…
  • 2020 American Transplant Congress

    Outcomes of Induction with T Lymphocyte-Depleting and IL-2 Receptor Blocking (IL-2RB) Antibodies in the Non-Broadly Sensitized Adult Deceased-Donor Kidney Transplant Recipients: Analysis in the Context of the CPRA Allocation System

    A. H. Santos Jr1, Y. Li2, K. Alquadan1, M. Leghrouz1, X. Wen3

    1Div. of Nephrology, Univ. of Florida, Gainesville, FL, 2Univ. of Florida, Gainesville, FL, 3Univ. of Rhode Island, Kingston, RI

    *Purpose: We studied outcomes of induction in non-broadly-sensitized adult deceased-donor kidney transplant recipients(DD-KTRs) in the context of the calculated panel reactive antibody (CPRA) allocation system.*Methods:…
  • 2020 American Transplant Congress

    Comparison of Short-Term Outcomes of Induction Therapy with Alemtuzumab versus Rabbit Antithymocyte Globulin in Lung Transplantation

    V. Liu, M. W. Soto-Arenall, A. Patel

    Pharmacy, Mayo Clinic, Jacksonville, FL

    *Purpose: To identify the short-term efficacy and safety outcomes of alemtuzumab (C1H) versus rabbit antithymocyte globulin (rATG) in lung transplant patients. The objectives are to…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 31
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences